Potential New 2nd line Therapy for PBC

Seladelpar (CymaBay) may replace obeticholic acid as a second line therapy for PBC. About 40% of patient with PBC may not respond to Ursodeoxycholic acid (UDCA) which is the current first line therapy. Similarly, half of patient's fail to respond to obeticholic acid.